the company has set up the opportunity for further 'licensing' deals to potentially be negotiated prior and post interim analysis in other geolocations by successfully partnering with Sandoz Group AG
that product development validation and the phase 3 trial 'funding' removes significant risk for other pharma considering their options in the insomnia + anxiety market
won't be surprised if further agreements are announced this year
just my view of course
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.69M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $3.015K | 753.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 36 | 23964317 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 16353356 | 19 |
View Market Depth
| Last trade - 15.57pm 17/06/2025 (20 minute delay) ? |
| AVE (ASX) Chart |